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In genetic frontotemporal dementia, cross-sectional studies have identiﬁed proﬁles of presymptomatic
neuroanatomical loss for C9orf72 repeat expansion, MAPT, and GRN mutations. In this study, we char-
acterize longitudinal gray matter (GM) and white matter (WM) brain changes in presymptomatic
frontotemporal dementia. We included healthy carriers of C9orf72 repeat expansion (n ¼ 12), MAPT (n ¼
15), GRN (n ¼ 33) mutations, and related noncarriers (n ¼ 53), that underwent magnetic resonance
imaging at baseline and 2-year follow-up. We analyzed cross-sectional baseline, follow-up, and longi-
tudinal GM and WM changes using voxel-based morphometry and cortical thickness analysis in SPM and
tract-based spatial statistics in FSL. Compared with noncarriers, C9orf72 repeat expansion carriers
showed lower GM volume in the cerebellum and insula, and WM differences in the anterior thalamic
radiation, at baseline and follow-up. MAPT mutation carriers showed emerging GM temporal lobe
changes and longitudinal WM degeneration of the uncinate fasciculus. GRN mutation carriers did not
show presymptomatic neurodegeneration. This study shows distinct presymptomatic cross-sectional
and longitudinal patterns of GM and WM changes across C9orf72 repeat expansion, MAPT, and GRN
mutation carriers compared with noncarriers.
 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hereditary frontotemporal dementia (FTD) is a neurodegenera-
tive disorder, predominantly caused by autosomal dominant ge-
netic mutations in theMAPTand GRN genes or a repeat expansion in
the C9orf72 gene (Renton et al., 2011; Seelaar et al., 2011).
Increasing evidence conﬁrms the presence of pathophysiological
and subsequent neuroanatomical changes in the presymptomatic
stage of genetic FTD and amyotrophic lateral sclerosis (ALS)
(Bertrand et al., 2018; Borroni et al., 2008; Caroppo et al., 2015; Cashgy, Erasmus Medical Center
Rotterdam, the Netherlands.
a).
r Inc. This is an open access article uet al., 2017; Dopper et al., 2014; Floeter et al., 2016; Jiskoot et al.,
2016, 2018; Lee et al., 2017; Meeter et al., 2016, 2017, 2018;
Papma et al., 2017; Pievani et al., 2014; Rohrer et al., 2015, 2013;
Walhout et al., 2015; Whitwell et al., 2011a). Previous magnetic
resonance imaging (MRI) studies have revealed gene-speciﬁc neu-
roimaging proﬁles in healthy carriers of pathogenic FTD mutations
(hereafter referred as “presymptomatic mutation carriers”)
(Bertrand et al., 2018; Borroni et al., 2008; Caroppo et al., 2015; Cash
et al., 2017; Dopper et al., 2014; Lee et al., 2017; Papma et al., 2017;
Pievani et al., 2014; Rohrer et al., 2015; Walhout et al., 2015). In
presymptomatic MAPT mutation carriers, lower gray matter (GM)
volume in the anterior temporal lobes has been found (Cash et al.,
2017; Rohrer et al., 2015), as well as lower fractional anisotropy
(FA) in thewhitematter (WM) of the right uncinate fasciculus when
using region of interest (ROI) analyses (Dopper et al., 2014). Innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the insula, temporal, and frontal lobes were shown (Caroppo et al.,
2015; Cash et al., 2017; Pievani et al., 2014; Rohrer et al., 2015) and
WM differences in the uncinate fasciculus and inferior fronto-
occipital fasciculus (Borroni et al., 2008; Dopper et al., 2014). Pre-
symptomatic C9orf72 repeat expansion carriers were characterized
by lower GM volume of the insula, thalamus, and cerebellum
(Bertrand et al., 2018; Cash et al., 2017; Lee et al., 2017; Papma et al.,
2017; Rohrer et al., 2015) and cortical thinning of the temporal lobe
(Walhout et al., 2015). These changes were already shown up to
25 years before estimated symptom onset (Rohrer et al., 2015). WM
loss in presymptomatic C9orf72 repeat expansion carriers included
the corticospinal tract, anterior thalamic radiation, inferior longi-
tudinal fasciculus, and the uncinate fasciculus (Bertrand et al., 2018;
Papma et al., 2017).
Although cross-sectional MRI studies in presymptomatic FTD
indicate that the disease process starts several years before clinical
symptom onset, studies that examine longitudinal presymptom-
atic GM and WM changes in speciﬁc mutations are scarce (Rohrer
et al., 2015; Schuster et al., 2015). Understanding longitudinal
presymptomatic FTDerelated brain changes is important, as it
enables both the identiﬁcation of vulnerable brain regions and the
timeframe and progression of brain changes, with important im-
plications for disease management and treatment (Schuster et al.,
2015). Progression of GM andWM changes in presymptomatic FTD
carriers may follow a gradual trajectory, similar to the presymp-
tomatic stage of other neurodegenerative diseases like Alz-
heimer’s disease (AD), shown in the Dominant Inherited
Alzheimer Network study (Bateman et al., 2012; Benzinger et al.,
2013; Kinnunen et al., 2018; Rohrer et al., 2015) but could also
deviate from ﬁndings in AD. For example, remarkable early brain
changes have been found in C9orf72 repeat expansion carriers,
which may indicate that C9orf72 repeat expansioneassociated
pathology knows an early start and progresses in a very slow
manner (Papma et al., 2017; Rohrer et al., 2015) or could even exist
as a neurodevelopmental disorder (Lee et al., 2017; Walhout et al.,
2015). On the other hand, previous research demonstrated that
atrophy rates during the symptomatic stage of FTD are twice as
high compared with patients with AD (Frings et al., 2014; Krueger
et al., 2010; Whitwell, 2010), with the fastest atrophy rates in FTD-
GRN patients (Whitwell et al., 2011b, 2015). An interesting issue
therefore is whether GRN pathology spreads in the last years
before symptom onset with a much faster, more explosive rate
(Jiskoot et al., 2018; Meeter et al., 2016). In the present study, we
aimed to investigate longitudinal GM and WM brain changes in
the presymptomatic stage of FTD, with a speciﬁc focus on FTD
genotypic patterns. Some previous studies have used voxel-based
morphometry (VBM; Borroni et al., 2008; Cash et al., 2017; Dopper
et al., 2014; Papma et al., 2017; Whitwell et al., 2011a) and others
used cortical thickness estimation for GM analyses in presymp-
tomatic FTD (Bertrand et al., 2018; Caroppo et al., 2015; Lee et al.,
2017; Pievani et al., 2014; Walhout et al., 2015). In this study, we
used both methods, and additional tract-based spatial statistics
(TBSS) for diffusion tensor imaging (DTI) analysis, to grasp the full
extent of presymptomatic GM and WM differences. Furthermore,
in normal brain aging (Hutton et al., 2009), and Parkinson’s dis-
ease (Gerrits et al., 2016), differences between results from VBM
and cortical thickness in the same sample have been demon-
strated, indicating that both methods could be complementary
(Hutton et al., 2009; Gerrits et al., 2016). We performed a 2-year
follow-up study in which we investigated cross-sectional and
longitudinal structural neuroimaging proﬁles using whole brain
VBM, cortical thickness analysis, and TBSS in presymptomatic
C9orf72 repeat expansion carriers, GRN or MAPT mutation carriers
and noncarriers.2. Methods
2.1. Study procedure
2.1.1. Study protocol and ethical approval
In the FTD Risk Cohort, we investigated ﬁrst-degree relatives of
FTD patients with one of the 3 major autosomal pathogenic muta-
tions (C9orf72, MAPT, GRN), as previously described in our baseline
study articles (Dopper et al., 2014; Papma et al., 2017). In this study,
every 2 years, participants underwentMRI of the brain, neurological
examination, and neuropsychological assessment (Jiskoot et al.,
2016, 2018). Knowledgeable informants (e.g., spouses, siblings)
completed questionnaires and were interviewed on changes in
cognition and/or behavior. Genotyping was performed at the base-
line study visit (Dopper et al., 2014; Papma et al., 2017). As a result,
participants were labeled as either mutation carriers or noncarriers.
All clinical investigators and participants were blinded for the par-
ticipants’ genetic status, unless participants underwent predictive
testing. The FTD Risk Cohort studywas approved by theMedical and
Ethical Review Committee of the Erasmus Medical Center, and
written informed consent has been obtained from all participants.
2.1.2. Subject inclusion
For the present study, we selected all presymptomatic participants,
either mutation carriers or healthy noncarrier family members, with a
baseline and 2-year follow-up MRI scan (n ¼ 113). We deﬁned partic-
ipantsaspresymptomaticbasedon: (1)not fulﬁllingestablishedcriteria
for possible FTD, primary progressive aphasia, or ALS (Gorno-Tempini
et al., 2011; Ludolph et al., 2015; Rascovsky et al., 2011), (2) the
absence of cognitive or behavioral disorders on extensive neuropsy-
chological assessmentor theNeuropsychiatric InventoryQuestionnaire
(NPI-Q) (Cummings,1997), asdescribedpreviously (Dopperet al., 2014;
Jiskoot et al., 2016, 2018; Papma et al., 2017), (3) the absence of signs of
motor neuron disease on neurological examination, (4) the presence of
normal cognitive functioning and behavior as reported by the partici-
pant and knowledgeable informant. The Frontotemporal
DementiaeClinical Rating Scale sum of boxes, Mini-Mental State Ex-
amination (MMSE), and NPI-Q were reported as functional, cognitive,
and behavioral screening instruments, respectively. The neuropsycho-
logical assessment included tests considering language, attention, ex-
ecutive functioning, memory, visuoconstruction, and social cognition,
for speciﬁcs see Jiskoot et al. (2018) and appendix A.
2.1.3. MRI acquisition
All participants underwent 3T T1-weighted and DTI at baseline
and 2-year follow-up using a standardized protocol (Philips
AchievaePhilips Medical Systems, Best, the Netherlands).
T1-weighted images were acquired with the following scanning
parameters: repetition time ¼ 9.8 ms, echo time ¼ 4.6 ms, ﬂip
angle ¼ 8, 140 slices, voxel size ¼ 0.88  0.88  1.20 mm3. DTI was
performed using single-shot echo planar imaging with 61 noncol-
linear gradient directions (1 b ¼ 0, 60 b ¼ 1000 s/mm2, repetition
time¼ 8250 ms, echo time¼ 80 ms, ﬂip angle¼ 90, 70 axial slices,
voxel size ¼ 2  2  2 mm3). Although MRI sequence parameters
were ﬁxed over time, during follow-up, a routine software update
by the manufacturer was installed at our MRI site, dated September
17, 2015 (Appendix B). MRI images were visually checked for gross
neurological pathology and artifacts, and excluded from analysis
when image quality proved insufﬁcient.
2.2. Image preprocessing and analysis
2.2.1. Voxel-based morphometry
Whole-brain T1-weighted images were preprocessed using the
longitudinal processing stream within the Computation Anatomy
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Wellcome Trust Center for Neuroimaging, London, UK) running in
MATLAB (2016b) (Mathworks, Natick, MA, USA). First, longitudinal
images from all subjects were rigidly aligned within-subjects and
the images were segmented into GM and WM and cerebrospinal
ﬂuid based on tissue probability. Afterward, segmented tissue im-
ages were aligned to standard space. Using diffeomorphic image
registration (DARTEL; Ashburner and Friston, 2000), we created a
study-speciﬁc GM template in standard space, and GM segmenta-
tions from all subjects were warped and normalized to this tem-
plate. After registration and normalization, GM images were
smoothed using a full-width at half-maximum kernel of 8 mm to
correct for individual brain differences. We performed cross-
sectional VBM analysis of variance (ANOVA) at the baseline and
follow-up to compare mutation groups (C9orf72, GRN, and MAPT)
with noncarriers and with each other, at both time points sepa-
rately. Follow-up GM volume images were subtracted from their
corresponding baseline maps and a longitudinal ANOVA was per-
formed to determine the amount of change in GM over time be-
tween groups (Dopper et al., 2016). Statistical analysis was
performed using a full factorial model with age, sex, scanner up-
date, and baseline total intracranial volume (TIV) as covariates. TIV
in mm3 was estimated through the segmentation and tissue vol-
ume calculation of the GM, WM, and cerebrospinal ﬂuid. The sta-
tistical threshold was set at p < 0.05 at cluster level, corrected for
multiple comparisons using familywise error (FWE). We also
explored clusters showing trends toward signiﬁcant difference at
pFWE < 0.1.
2.2.2. Cortical thickness
We extended the standard brain segmentation protocol from the
Computation Anatomy Toolbox in SPM12, as mentioned previously,
with surface-based cortical thickness estimation for baseline and
follow-up images, using projection-based thickness (Dahnke et al.,
2013). For statistical analysis, we used the same models as for the
VBM analysis, and performed cross-sectional baseline and follow-up
analyses to compare the effect of mutation group (C9orf72, GRN,
MAPT) with noncarriers and each other. We performed an ANOVA
with age, sex, and scanner update (for follow-up analysis) as covariates
and thresholded at pFWE < 0.05 at cluster level. We also explored
clusters showing trends toward signiﬁcant difference at pFWE< 0.1. For
the longitudinal analysis, follow-up cortical thickness images were
subtracted from their corresponding baselinemaps, and a longitudinal
ANOVA was performed to determine the amount of change in thick-
ness over time for each participant, also at pFWE < 0.05, corrected for
age, sex, and scanner update. However, as recommended, the cortical
thickness analyses were not adjusted for baseline TIV (http://www.
neuro.uni-jena.de/cat12/CAT12-Manual.pdf).
2.2.3. Tract-based spatial statistics
Diffusion-weighted images were preprocessed using TBSS (part
of the FMRIB Software Library, Smith et al., 2004) as described
previously (Dopper et al., 2014; Papma et al., 2017). We used the
FMRIB58_FAederived skeleton instead of a study-speciﬁc skeleton
to allow for comparisons across the baseline, follow-up, and lon-
gitudinal analyses. Skeletonized FA and mean diffusivity (MD) im-
ages were fed into voxelwise group statistics for cross-sectional
baseline and follow-up analyses to investigate the effect of muta-
tion group. For the longitudinal analysis, follow-up FA and MD
images were subtracted from their corresponding baseline maps to
determine the amount of change inWM integrity over time for each
participant and compared between groups with an ANOVA. Com-
parisons were performed using permutation-based testing (5000
permutations), with age, gender, the scanner update, and baseline
TIV as covariates. The statistical threshold was set at pFWE < 0.05.2.3. Statistical analyses
Other statistical analyses were performed using SPSS Statistics
24.0 for Windows (SPSS Inc, Chicago, IL, USA). Group differences in
sex were analyzed using Pearson c2 tests. Age at time of MRI scan
was compared by means of one-way ANOVA. Because of a skewed
distribution, the MMSE and NPI-Q scores were analyzed with a
Kruskal-Wallis test. Composite cognitive domain scores for lan-
guage, attention, executive functioning, memory, visuocon-
struction, and social cognition were computed and evaluated
between groups as described previously (Jiskoot et al., 2018) and
reported in Appendix A. As the distribution of neuropsychological
test data was predominantly skewed, we applied Kruskal-Wallis
tests, with post hoc Mann-Whitney-U tests for composite cogni-
tive domain scores. We applied a signiﬁcance level of p < 0.05 with
post hoc Bonferroni comparisons for all statistical analyses.
3. Results
3.1. Subjects
DNA sequencing assigned participants either to the C9orf72
repeat expansion carrier (n ¼ 12), MAPT mutation carrier (n ¼ 15),
GRN mutation carrier (n ¼ 33), or, in the case of mutation-negative
family members, to the noncarrier group (n ¼ 53). One presymp-
tomaticMAPTmutation carrier was excluded from GM analysis due
to a large cerebellar cyst, and one presymptomatic C9orf72 repeat
expansion carrier was excluded due to registration and recon-
struction errors. GM analysis was carried out in 11 C9orf72 repeat
expansion, 14 MAPT, and 33 GRN mutation carriers, and 53 non-
carriers and WM analysis in 12 C9orf72 repeat expansion, 14 MAPT,
and 28 GRN mutation carriers, and 50 noncarriers. Nine subjects
were excluded fromWM analysis due to signal dropout (n ¼ 6) and
motion artifacts (n ¼ 3) on the DTI scan. All participants were pre-
symptomatic at both the baseline and follow-up visit, with Fronto-
temporal DementiaeClinical Rating Scale sum of boxes ¼ 0 at both
time points (Table 1). An overview of demographic characteristics is
presented in Table 1. MAPT mutation carriers were signiﬁcantly
younger than noncarriers and GRNmutation carriers. Other subject
characteristics were similar across groups, including screening
measures for clinical symptoms such as the MMSE and NPI-Q. None
of the participants scored below 2 standard deviations on neuro-
psychological tests. At baseline, all groups performed similar on
composite cognitive domains (Appendix A). At follow-up, C9orf72
repeat expansion carriers and noncarriers performed signiﬁcantly
worse than GRNmutation carriers on social cognition (Appendix A).
3.2. C9orf72 repeat expansion carriers versus noncarriers
3.2.1. Gray matter
Cross-sectional VBM analysis at baseline showed lower GM
volume in the cerebellum, insula, left frontal, and left planum
temporale in C9orf72 repeat expansion carriers compared with
noncarriers (Fig. 1A, Appendix C.1), whereas cortical thickness
analysis showed thinning in the right postcentral gyrus and a trend
toward thinning of the left precentral gyrus (at pFWE ¼ 0.060).
Cross-sectional VBM analysis at 2-year follow-up showed lower GM
volume in C9orf72 repeat expansion carriers compared with non-
carriers in the thalamus, cerebellum, and several bilateral cortical
regions, that is, orbitofrontal and insular cortices, and the post-
central gyrus (Fig. 1A, Appendix C.1). In addition, cortical thickness
analysis showed cortical thinning in bilateral precentral gyrus and
right superior parietal lobule in C9orf72 repeat expansion carriers
compared with noncarriers (Fig. 1B, Appendix C.2). Longitudinal
VBM and cortical thickness analyses did not reveal any signiﬁcant
Table 1
Demographic characterization
Variable Noncarriers MAPT GRN C9orf72 p-value
Subjects (male) 53 (24) 15 (9) 33 (11) 12 (2) 0.094
Mean age (SD) 50.72 (10.73) 41.77 (9.50) 52.10 (7.53) 49.70 (12.36) 0.010a
<35 3 2 0 1
35e50 18 11 13 6
50e65 29 1 18 4
65þ 3 1 2 1
Baseline
MMSE 29.13 (1.21) 29.47 (0.64) 29.09 (1.40) 29.58 (0.67) 0.657
NPI-Q 0.19 (0.54) 1.50 (3.75) 0.70 (1.42) 0.55 (1.21) 0.401
Follow-up
MMSE 29.26 (1.23) 28.80 (2.11) 28.84 (1.57) 29.25 (0.96) 0.580
NPI-Q 0.42 (0.88) 2.08 (5.77) 0.18 (0.48) 1.18 (1.66) 0.128
Key: FTD-CDR, Frontotemporal DementiaeClinical Rating Scale sum of boxes; MMSE, Mini-Mental State Examination; NPI-Q, Neuropsychiatric Inventory Questionnaire; SD,
standard deviation.
Scores for MMSE and NPI-Q are presented as mean scores (SD).
a MAPT mutation carriers signiﬁcantly younger than noncarriers and GRN mutation carriers.
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were no brain regions where noncarriers showed lower GM volume
or cortical thinning compared with C9orf72 carriers at the baseline,
follow-up, or longitudinally.
3.2.2. White matter
Cross-sectional analyses at baseline revealed lower FA in C9orf72
repeat expansion carriers in frontotemporal tracts compared withFig. 1. e Gray matter differences in C9orf72 repeat expansion carriers. (A) VBM comparisons
Cortical thickness analysis, pFWE < 0.05. Thinning in C9orf72 repeat expansion carrier
morphometry.noncarriers, predominantly located in the bilateral corticospinal
tract and anterior thalamic radiation, the right inferior fronto-
occipital fasciculus, and superior longitudinal fasciculus (Fig. 2A,
Appendix C.3) and higher MD in almost the entire skeleton when
compared with noncarriers (Fig. 2B, Appendix C.3). At follow-up,
we found lower FA and increased MD in the same tracts as base-
line analyses, although to a lesser extent (Fig. 2B, Appendix C.3). We
did not ﬁnd any signiﬁcant longitudinal changes in the WM (both, pFWE < 0.05. GM of C9orf72 repeat expansion carriers compared with noncarriers. (B)
s compared with noncarriers. Abbreviations: GM, gray matter; VBM, voxel-based
Fig. 2. White matter differences in C9orf72 repeat expansion carriers. (A) Lower FA in C9orf72 repeat expansion carriers compared with noncarriers, pFWE < 0.05. (B) Higher MD in
C9orf72 repeat expansion carriers compared with noncarriers, pFWE <0.05. Abbreviations: FA, fractional anisotropy; MD, mean diffusivity.
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noncarriers, or vice versa.3.3. MAPT mutation carriers versus noncarriers
3.3.1. Gray matter
Cross-sectional VBM and cortical thickness analyses at baseline
showed no GM volume differences in MAPT mutation carriers
compared with noncarriers. VBM analysis at follow-up showed
lower GM volume in the left temporal pole of MAPT mutation car-
riers (Fig. 3A, Appendix C.1), and cortical thickness analysis at
follow-up showed a trend toward cortical thinning of the right
inferior temporal lobe (at pFWE ¼ 0.072; Fig. 3B, Appendix C.2).
Longitudinal VBM analysis showed signiﬁcant GM volume decline
in the hippocampus compared with noncarriers (Fig. 3A, Appendix
C.1), whereas cortical thickness analysis did not pick up any longi-
tudinal changes. Noncarriers did not show areas of GM volume
decline or cortical thinning compared withMAPTmutation carriers.
3.3.2. White matter
Baseline or follow-up cross-sectional analyses did not show any
signiﬁcant WM differences between MAPT mutation carriers and
noncarriers. Longitudinal analyses showed signiﬁcant lower FA in
the left uncinate fasciculus, the left anterior thalamic radiation, and
the left inferior fronto-occipital fasciculus ofMAPTmutation carriers
compared with noncarriers (Fig. 4, Appendix C.3). There were nosigniﬁcant changes in MD over time between MAPT mutation car-
riers and noncarriers.
3.4. GRN mutation carriers versus noncarriers
GRN mutation carriers did not show GM volume or cortical
thickness differences compared with noncarriers at baseline,
follow-up, or in longitudinal analyses. In addition, noncarriers did
not showany loss of GM volume or cortical thinning comparedwith
GRN mutation carriers. Furthermore, we did not ﬁnd signiﬁcant
differences in FA or MD between GRN mutation carriers and
noncarriers.
3.5. Comparisons between mutation groups
3.5.1. Gray matter
C9orf72 repeat expansion carriers showed lower GM volume in
the cerebellum, thalamus, and insula at both baseline and follow-up
when compared with MAPT mutation carriers (Appendix C.1).
Compared with GRN mutation carriers, C9orf72 repeat expansion
carriers had lower GM volume in the cerebellum, thalamus, insula,
and frontal cortical regions at baseline and follow-up (Appendix
C.1). In addition, cortical thickness analyses showed thinning in
C9orf72 repeat expansion carriers compared with GRN mutation
carriers in the precentral and postcentral gyrus, at baseline and
follow-up (Appendix C.2). We did not ﬁnd longitudinal VBM or
cortical thickness changes in C9orf72 repeat expansion carriers
Fig. 3. Gray matter changes inMAPTmutation carriers. (A) VBM comparisons, pFWE< 0.05. GM ofMAPTmutation carriers compared with noncarriers. (B) Cortical thickness analysis,
pFWE < 0.05. Thinning in MAPT mutation carriers compared with noncarriers. Abbreviations: GM, gray matter; VBM, voxel-based morphometry.
J.L. Panman et al. / Neurobiology of Aging 76 (2019) 115e124120compared with GRN orMAPTmutation carriers. We found thinning
of the right temporal pole in MAPT mutation carriers compared
with GRNmutation carriers at the follow-up (Appendix C.2) but not
at baseline or longitudinally. There were no VBM or cortical thick-
ness changes in MAPT mutation carriers compared with C9orf72
repeat expansion carriers or changes in GRN mutation carriers
compared with MAPT mutation carriers or C9orf72 repeat expan-
sion carriers at baseline, follow-up, or longitudinally.
3.5.2. White matter
C9orf72 repeat expansion carriers had lower FA and higher MD
in the bilateral anterior thalamic radiation and forceps minor and
major, right uncinate, and inferior fronto-occipital fasciculus and
corticospinal tract at baseline compared with MAPT mutation car-
riers (Appendix C.3). At follow-up, C9orf72 repeat expansion car-
riers had lower FA in the bilateral anterior thalamic radiation, right
temporal tract, and left frontal tract compared withMAPTmutation
carriers, without differences in MD at follow-up. Compared with
GRN mutation carriers, we found higher MD in C9orf72 repeat
expansion carriers in bilateral temporal and parietal tracts at
baseline and in the right superior longitudinal and inferior fronto-
occipital fasciculus at follow-up (Appendix C.3). We did not ﬁnd
differences in FA between C9orf72 repeat expansion carriers and
GRN mutation carriers. Longitudinal analysis did not reveal any
signiﬁcant differences in FA or MD between C9orf72 repeat
expansion carriers and MAPT or GRN mutation carriers. ComparedFig. 4. Longitudinal FA degeneration in MAPT mutation carriers comparedwith GRN mutation carriers, we found a longitudinal decline of FA
in MAPT mutation carriers in left frontal tracts, predominantly in
the uncinate and inferior fronto-occipital fasciculus (Appendix C.3)
No other FA or MD changes were found in MAPT mutation carriers
at baseline or follow-up compared with GRN mutation carriers or
C9orf72 repeat expansion carriers. Compared with MAPT mutation
carriers, GRN mutation carriers had lower FA at follow-up in left
frontal tracts, predominantly the forceps major, but not at baseline
or longitudinal analyses (Appendix C.3). We did not ﬁnd changes in
FA or MD in GRN mutation carriers compared with C9orf72 repeat
expansion carriers.4. Discussion
In this longitudinal MRI study, we found presymptomatic GM
and WM changes in C9orf72 repeat expansion carriers and MAPT
mutation carriers at cross-sectional and longitudinal analyses, but
not in GRN mutation carriers. Compared with noncarriers, pre-
symptomatic C9orf72 repeat expansion carriers showed prominent
lower GM volume in the cerebellum, thalamus, insula, and cortical
frontal and temporal regions, seemingly stable over time. WM
differences in C9orf72 repeat expansion carriers were found in
subcortical and posterior tracts, particularly the anterior thalamic
radiation. MAPT mutation carriers were characterized by left-sided
GM volume loss and right-sided cortical thinning in the temporalwith noncarriers, pFWE < 0.05. Abbreviation: FA, fractional anisotropy.
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left-sided frontotemporal tracts when compared with noncarriers.
Our longitudinal ﬁndings indicate that the presymptomatic
stage of C9orf72 repeat expansion is characterized by a stable lower
GM volume in the cerebellum, thalamus, insula, and several frontal
and temporal regions (Rohrer et al., 2015). The prominent cere-
bellar atrophy was in line with other presymptomatic cross-
sectional studies (Bertrand et al., 2018; Cash et al., 2017; Papma
et al., 2017), although the study of Rohrer et al. suggested a tem-
poral ordering of presymptomatic changes with atrophy in the
thalamus, insula, occipital, frontal, and temporal lobe preceding
cerebellar atrophy, already 25 years before estimated symptom
onset (Rohrer et al., 2015). Due to methodological differences (e.g.,
mixed effect models based on ROI data vs. whole-brain analyses,
percentage of TIV vs. absolute measures, and the use of estimated
years of onset), it is difﬁcult to compare our ﬁndings to the GENFI
consortium article. However, it is important to appreciate the fact
that C9orf72 repeat expansion mutation carriers seem to show
remarkable early GM changes (Bertrand et al., 2018; Rohrer et al.,
2015; Walhout et al., 2015). This has been explained previously as
either following a trajectory with an early onset and very slow
progression of atrophy (Rohrer et al., 2015) or as a neuro-
developmental disorder (Lee et al., 2017; Walhout et al., 2015).
Although our results agree with early GM and WM differences in
presymptomatic C9orf72 repeat expansion carriers compared with
noncarriers, we cannot comment on the underlying mechanism.
Stable lower GM volume may indicate a neurodevelopmental pro-
cess but could also mean that our 2-year follow-up period is not
sufﬁcient to detect very slow progressive brain changes.
Our ﬁndings of extensive subcortical WM differences at baseline
between C9orf72 repeat expansion carriers and noncarriers are in
line with previous studies, indicating early involvement of the
thalamic radiation in symptomatic C9orf72 carriers, with both the
ALS and FTD phenotype (Bede et al., 2013; Mahoney et al., 2012;
Schonecker et al., 2018). Furthermore, in this study, we showed
that these WM differences remain relatively stable during a 2-year
period. Functional connectivity loss in presymptomatic C9orf72
repeat expansion carriers has been found in the thalamus and the
salience network (Lee et al., 2017). Decreasing WM connections in
the thalamus in C9orf72 repeat expansion may underlie functional
connectivity and neuronal loss in areas related to the salience
network, such as the insula and orbitofrontal cortex (Seeley, 2010;
Uddin, 2015), which is strongly associated with FTD (Seeley, 2010;
Zhou et al., 2010).
The GM and WM regions that were affected in our cross-
sectional analyses in C9orf72 repeat expansion carriers were in
accordance with expected pathology in FTD and ALS (Floeter et al.,
2016), for example, orbitofrontal, temporal, and insula atrophy are
associated with behavioral variant FTD (Gordon et al., 2016; Meeter
et al., 2017; Seelaar et al., 2011), and changes in the precentral and
postcentral gyri may eventually underlie ALS (Chio et al., 2014;
Turner et al., 2012). Our results of subcortical WM loss could well
ﬁt both FTD and ALS phenotypes of the C9orf72 repeat expansion
(Bede et al., 2013; Mahoney et al., 2012; Schonecker et al., 2018).
When performing MRI group analysis in speciﬁcally presymptom-
atic C9orf72 repeat expansion carriers, it is important to keep in
mind the heterogeneity in the disease phenotype, for example, FTD
or ALS, memory or psychiatric disorders (Floeter et al., 2016). In line
with this reasoning, the location of emerging presymptomatic GM
volume loss might predict the disease phenotype of an individual
C9orf72 repeat expansion carrier. And, both the onset of patho-
physiological changes and the affected brain regions may be highly
variable across patients, which complicates comparisons between
cross-sectional group analyses and claims on the onset of neuro-
degeneration. The mean disease onset in C9orf72 repeat expansioncarriers has been reported at 50 years of age, ranging from early
adulthood to old age, from 27 to 83 years, and large intrafamily
heterogeneity in disease onset and phenotype is common
(Olszewska et al., 2016; Van Mossevelde et al., 2017). Therefore, the
disease trajectory of C9orf72 repeat expansion carriers may be
elucidated by longer follow-up periods and longitudinal modeling
with both presymptomatic and symptomatic carriers with different
phenotypes.
At follow-up, we found cortical GM thinning in the right tem-
poral lobe in presymptomatic MAPT mutation carriers and GM
volume loss in the left temporal pole and parahippocampal gyrus,
which is line with previous cross-sectional presymptomatic MAPT
studies (Cash et al., 2017; Dopper et al., 2014; Rohrer et al., 2015),
and resembles the atrophy pattern found in symptomatic MAPT
carriers (Gordon et al., 2016; Rohrer et al., 2010; Whitwell et al.,
2012, 2015). Furthermore, GM volume in the right hippocampus
signiﬁcantly decreased over time. In addition, we found longitudi-
nal WM changes in left-sided frontotemporal association tracts
including the uncinate fasciculus, which connects structures of the
limbic system in the temporal lobe with the orbitofrontal cortex
and has been indicated to underlie inhibition and impulse control
(Hornberger et al., 2011; Olson et al., 2015). Although our results are
somewhat contradicting in asymmetry, and involve left or right
hemispheres in VBM and cortical thickness analyses, this may
suggest emerging pathophysiological changes in both temporal
lobes ofMAPTmutation carriers. Therefore, as previously proposed,
VBM and cortical thickness analyses may be applied as comple-
mentary methods (Hutton et al., 2009; Gerrits et al., 2016). VBM
relies on a mixture of measurements in cortical thickness, cortical
surface areas, and folding of the gyri (Ashburner and Friston, 2000).
When used together, voxel-based cortical thickness analysis could
aid understanding of underlying GM differences, especially in age-
related brain changes (Hutton et al., 2009; Pereira et al., 2012).
Although the MAPT mutation carriers were younger (mean age:
41.77) than noncarriers (mean age: 50.72) and GRN mutation car-
riers (mean age: 52.10), mean onset in MAPT mutations has been
reported at 55 (Olszewska et al., 2016) and ranges till before 40 in
some families (Seelaar et al., 2011). Therefore, most of our MAPT
mutation carriers are likely to be within 1 or 2 decades before
symptom onset. Our present ﬁndings combined with previous
functional MRI, cognitive, and GM studies (Jiskoot et al., 2016;
Rohrer et al., 2015; Whitwell et al., 2011a), indicate that GM and
WM loss in presymptomatic MAPT carriers gradually progressed in
a period of 5 to 10 years before symptom onset, starting in the
temporal lobe, followed by slowly progressive cognitive decline.
The absence of any signiﬁcant changes in a relatively large
cohort of presymptomatic GRN mutation carriers compared with
noncarriers in the present study is a remarkable ﬁnding, supported
by previous cross-sectional studies (Cash et al., 2017; Dopper et al.,
2014). One may argue that in a voxel-based groupwise analysis,
subtle changes may remain undetected due to the typical, but in the
presymptomatic stage, not yet visible asymmetrical left- or right-
sided atrophy in GRN mutation carriers (Cash et al., 2017; Rohrer
et al., 2010). Yet, Rohrer et al. found GM volume decline 15 years
before expected age of onset with linear mixed modeling in GRN
mutation carriers when combining the right insula and left insula
(Rohrer et al., 2015). An alternative explanation might be that
pathophysiological changes due to GRN mutation carriers spread
quite rapidly, with extensive damage in a short period before
symptom onset (Cash et al., 2017). Such hypothesis may be sup-
ported by the rapid decrease in cognitive functioning and strong
increase in cerebrospinal ﬂuid NfL levels in the short transitional
stage from presymptomatic till symptom onset in GRN mutation
carriers (Jiskoot et al., 2018; Meeter et al, 2016, 2017, 2018; Rohrer et
al., 2008), accompanied by quickly expanding atrophy on
J.L. Panman et al. / Neurobiology of Aging 76 (2019) 115e124122T1-weighted imaging, starting 18 months before symptom onset
(Rohrer et al., 2008). Because the asymmetric left- or right-sided
pattern of atrophy differs in patients even from the same families
(Gordon et al., 2016; van Swieten and Heutink, 2008; Whitwell
et al., 2012), and therefore groupwise neuroimaging analyses in
presymptomatic carriers may result in a less useful biomarker for
GRNmutation carriers, other biomarkers that measure pathological
changes may be necessary. In GRN mutation carriers, mean symp-
tom onset may be 65 years but ﬂuctuates within families up to
20 years (Olszewska et al., 2016; Seelaar et al., 2011). Rapid changes
over time implicate that 6- to 12 months monitoring from sus-
ceptible ages, for example, from w45 years onward may be indi-
cated in GRN mutation carriers (Onyike and Diehl-Schmid, 2013;
Seelaar et al., 2011; van Swieten and Heutink, 2008) to enable
prescription ofdfuturedpharmacological treatment before onset
of the neurodegenerative process.
Key strengths of our study are the longitudinal measurements
in a large cohort of presymptomatic FTD mutation carriers and
the single-center standardized MRI protocol with stable
sequence parameters over time. Longitudinal multimodal im-
aging adds signiﬁcant value over cross-sectional or unimodal
imaging, as it enables insight into the proﬁle and trajectory of
brain changes. However, our current cross-sectional baseline
ﬁndings in C9orf72 repeat expansion carriers were not
completely compliant with previous baseline ﬁndings of our
group (Papma et al., 2017), and can be explained by the current
increased control group that could have led to an increase in
statistical power. Especially for the C9orf72 repeat expansion and
MAPT mutation group, our sample size was quite small, and re-
sults in these mutation groups may have been driven by indi-
vidual carriers. ROI analyses could overcome some of the power
problems, as it signiﬁcantly reduces the strictness of the multiple
comparisons correction, however, with the risk that unexpected
brain regions may be overlooked. Before choosing predeﬁned
ROIs, explorative whole-brain analyses in the presymptomatic
stage are necessary, which we aimed to accomplish with our
present study. Furthermore, when using mixed-effects models
and longer follow-up periods, ROI-based analysis could elucidate
on the rate of brain changes and the acceleration related to time
toward symptom onset or increasing age, as, for example, in the
GENFI study (Rohrer et al., 2015). However, using estimated years
to onset in longitudinal mixed-effects models may be disad-
vantageous, as large intrafamiliar heterogeneity in age at disease
onset has been reported in genetic FTD mutations (Olszewska
et al., 2016, Seelaar et al., 2011; Van Mossevelde et al., 2017).
Our follow-up and longitudinal results may have been slightly
compromised by a software upgrade on our MRI scanner (Shuter
et al., 2008; Takao et al., 2012, 2013). To account for possible
signal changes, we added a covariate to our statistical analyses,
minimizing the potential effects of the scanner update.
In conclusion, this study shows distinct presymptomatic GM and
WM alterations across C9orf72 repeat expansion andMAPT and GRN
mutations carriers. Presymptomatic neuroanatomical changes in
C9orf72 repeat expansion carriers, in particular, affecting the cere-
bellum and subcortical GM and WM, may be present early in the
disease process, and our results point toward a possible neuro-
developmental disorder. In MAPT mutation carriers, our results
suggest gradual progression of neurodegeneration, starting with
GM volume loss, cortical thinning, and WM integrity loss in the
temporal lobes. Rapid pathophysiological and neuroanatomical
progressionmay reﬂect the trajectory before symptom onset in GRN
mutation carriers, as we found no cross-sectional and longitudinal
changes in a relatively large group of presymptomatic GRN muta-
tion carriers. Complicating factors when performing longitudinal
group analyses in presymptomatic FTD mutation carriers are anasymmetric pattern of atrophy and heterogeneity in pathophysi-
ology, phenotype, and onset age. Other studies may conﬁrm and
elaborate on our longitudinal ﬁndings, increasing insight in the
timing and progression of genotype- and phenotype-related pre-
symptomatic neurodegeneration in genetic FTD.
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